Our systematic review and network meta-analysis (NMA) mark a significant step forward in evaluating the efficacy of daprodustat across various doses, alongside recombinant human erythropoietin (rhEPO) and placebo, in treating anemia among dialysis-dependent chronic kidney disease (CKD) patients. The gene discussed is EPO; the disease is anemia.